We announced the establishment of CHI’s new Center of Applied Sustainability to provide solutions to reduce customers’ carbon footprints.
We communicated a collaboration with Exogenus Therapeutics to develop Exo-101, its exosome-based lead candidate.
We launched our simplified and streamlined operating model to support our One Lonza vision and strategy.
We also announced the completion of our share buyback program.
We announced a collaboration with Ethris to develop spray-dried mucosal mRNA vaccines.
We joined the Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) to enhance our service offering for specialty and enhanced drug product and particle technologies.
We welcomed Juan Andres, Eric Drapé and David Meline as new members of the Board of Directors at our Annual General Meeting.
We shared a qualitative update on our Q1 2025 performance.
Andreas Bohrer was appointed as Chief Legal & Corporate Affairs Officer and joined Lonza’s Executive Committee.
We also launched our Design2Optimize™ Platform to streamline API development.
We launched our Next Generation 4D-Nucleofector® LV Unit PRO for improved electroporation in GMP manufacturing.
We communicated strong Half-Year 2025 financial results.
We announced our collaboration with RION to manufacture exosome based therapeutics.
We welcomed Jason Berndt as Head of Group Operations, and Maria Soler Nunez was appointed Chief Quality Officer.
We launched TheraPEAK® AmpliCell® Cytokines and TheraPEAK 293-GT® Medium to expand our GMP solutions for cell and gene therapy.
We received Swissmedic approval for our highly potent biologics drug product filling line in Stein (CH).
We shared a qualitative update on our Q3 2025 performance.
We announced the planned acquisition of Redberry to expand our Bioscience testing offering.
Our Cocoon® Platform received Advanced Manufacturing Technologies (AMT) designation from the U.S. FDA.
